Characterizing human abuse potential (HAP) liability
Characterizing human abuse potential liability can be dependent on many factors, including pharmacology, pharmacokinetics, and the intended population. We can help.
News at CenExel
CenExel Acquires Apex Innovative Sciences
Salt Lake City, June 16, 2022 /GlobeNewswire/ — CenExel announces the acquisition of Apex Innovative Sciences, parent company of Collaborative Neuroscience Research (CNS) and Hassman...
Cali Biosciences Initiates Phase 2b Study of Long-Acting Ropivacaine for Non-Opioid Treatment of Post-Operative Pain
SAN DIEGO, August 12, 2021 /PRNewswire/ — Cali Biosciences Co., Ltd. (hereinafter referred to as “CaliBio”), a global biopharmaceutical company focused on the research and...
Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™
Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™ SAN DIEGO, July 21,...
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours – ZYNRELEF is the first...
